Inhibition of PFKFB3 in Macrophages Has a Dual Effect on Tumor-Regulating Lipid Metabolism
Authors:
- Elena ShmakovaESElena Shmakova
- Tatiana SudarskikhTSTatiana Sudarskikh
- Kseniia ShalyginaKSKseniia Shalygina
- Vitaliy ChagovetsVCVitaliy Chagovets
- Natalia StarodubtsevaNSNatalia Starodubtseva
- Alisa TokarevaATAlisa Tokareva
- Anastasia NovoselovaANAnastasia Novoselova
- Vladimir FrankevichVladimir Frankevich
- Anna TarasovaATAnna Tarasova
- Dmitry KostromitskyDKDmitry Kostromitsky
- Alexey DobrodeevADAlexey Dobrodeev
- Sergey Afanas’evSASergey Afanas’ev
Open Access
- 24 December 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (1) , 217
Abstract
Colorectal cancer is the third most common cancer worldwide, making lymph node recovery critical for treatment decisions and prognosis. Within the colorectal tumor microenvironment, the metabolic programming of tumor-associated macrophages (TAMs) can drive both pro- and anti-tumor responses, yet the specific glycolytic pathways governing their pro-metastatic conversion present promising therapeutic targets. This study investigated the role of glycolysis activating enzyme 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) in mediating TAMs metabolic polarization, and its potential as a therapeutic target. PFKFB3 expression was found to be predominant in TAMs in CRC tumor samples. Lipidomic analysis performed by HPLC-MS/MS revealed that PFKFB3 inhibition altered glycerophospholipid metabolism (p = 6.13 × 10−10), and shifted TAMs toward sphingolipid-mediated immunosuppressive metabolism. PFKFB3 activity was associated with a specific reduction in asparagine availability, potentially pointing to a targeted reprogramming of amino acid metabolism supporting distinct TAM functions under conditions of intra-tumoral metabolic stress. These findings highlight PFKFB3 as an essential regulator of TAMs pro-tumoral metabolism in CRC, particularly in colon cancer.Keywords
All Related Versions
Funding Information
- Russian Science Foundation (24-25-00455)
This publication has 32 references indexed in Scilit:
- Covalent Organic Frameworks‐Delivered Reuterin Drives Trained Immunity in Tumor‐Associated Macrophages to Enhance Melanoma Immunotherapy via Glycerophospholipid MetabolismAdvanced Science, 2025
- The role of SPP1+TAMs in cancer: Impact on patient prognosis and future therapeutic targetsInternational Journal of Cancer, 2025
- Immunometabolism of tumor-associated macrophages: A therapeutic perspectiveEuropean Journal of Cancer, 2025
- Targeting of TAMs: can we be more clever than cancer cells?Cellular & Molecular Immunology, 2024
- The composition of linoleic acid and conjugated linoleic acid has potent synergistic effects on the growth and death of RAW264.7 macrophages: The role in anti-inflammatory effectsInternational Immunopharmacology, 2024
- An ERK5-PFKFB3 axis regulates glycolysis and represents a therapeutic vulnerability in pediatric diffuse midline gliomaCell Reports, 2023
- Toll-Like Receptors Induce Signal-Specific Reprogramming of the Macrophage LipidomeCell Metabolism, 2020
- PTGES/PGE2 signaling links immunosuppression and lung metastasis in Gprc5a-knockout mouse modelOncogene, 2020
- Sphingolipids as mediators of inflammation and novel therapeutic target in inflammatory bowel disease2020
- Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinomaJournal of Hepatology, 2019